12 completed, 3 active not recruiting, 1 available, 1 no longer available. 7 Phase 3, 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Active not recruiting 3 |
| Phase 2 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
Follow DBV Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) DBV712 250 mcg, Placebo - Allergy, Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 480 | 2025-06-24 | 2026-07-22 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age DBV712, Placebo - Allergy, Peanut | Phase 3 | Active not recruiting | DBV Technologies | 600 | 2023-02-21 | 2026-01-22 |
| Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children DBV1605 - Cow's Milk Allergy | Phase 2 | Unknown | DBV Technologies | 230 | 2020-08-28 | 2022-08-11 |
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children DBV712 250 mcg - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 304 | 2018-12-06 | 2026-10-28 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects DBV712 IHRP - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 27 | 2017-11-24 | 2019-07-26 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 414 | 2017-07-31 | 2024-12-16 |
| Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Viaskin Peanut 250µg - Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 300 | 2017-01-23 | 2020-12-02 |
| Safety Study of Viaskin Peanut to Treat Peanut Allergy Viaskin Peanut 250 µg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 393 | 2016-10-25 | 2026-10-08 |
| Viaskin Pertussis Vaccine Trial Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo - Whooping Cough | Phase 1 | Completed | DBV Technologies | 102 | 2016-09-05 | 2020-03-02 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Viaskin Peanut 250mcg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 500 | 2015-12-01 | 2025-06-18 |
| Milk Patch for Eosinophilic Esophagitis Viaskin Milk 500 mcg, Viaskin Placebo - Eosinophilic Esophagitis, Milk Allergy | Phase 2 | Completed | Children's Hospital of Philadelphia | 20 | 2015-10-01 | 2019-07-10 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg - Food Allergy | Phase 1 / Phase 2 | Completed | DBV Technologies | 198 | 2014-11-01 | 2024-11-20 |
| Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Viaskin Peanut 250 mcg - Peanut Allergy | Phase 2 | Completed | DBV Technologies | 171 | 2013-09-01 | 2022-06-30 |
| Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg - Peanut Allergy | Phase 2 | Completed | DBV Technologies | 221 | 2012-08-01 | 2021-10-27 |
| Epicutaneous Immunotherapy in Peanut Allergy in Children Epicutaneous Immunotherapy, placebo of peanut - Peanut Allergy | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 60 | 2010-08-01 | 2026-08-21 |
| Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy Whole peanut extract, Placebo formulation - Peanut Allergy | Phase 1 | Completed | DBV Technologies | 100 | 2010-07-01 | 2012-03-23 |
| Viaskin® Peanut (DBV712) Expanded Access Protocol Viaskin Peanut - Peanut Allergy | No longer available | DBV Technologies | 2021-05-28 | |||
| Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children DBV712 250 mcg - Peanut Allergy | Available | DBV Technologies | 2026-01-15 |
Peanut Hypersensitivity (14) · Food Hypersensitivity (8) · Hypersensitivity, Immediate (3) · Milk Hypersensitivity (3) · Hypersensitivity (2) · Nut and Peanut Hypersensitivity (2) · Eosinophilic Esophagitis (1) · Whooping Cough (1)
Boostrix (1)
United States (15) · Canada (10) · France (6) · Australia (5) · Ireland (5) · Netherlands (5) · Germany (4) · United Kingdom (3) · Spain (2) · Italy (1) · Lithuania (1) · Poland (1) · Switzerland (1)
Antonella Cianferoni, MD, PhD (1) · Christophe Dupont, MD, PhD (1) · Claire Anne Siegrist, M.D (1) · David M Fleischer, MD (1)
PMID 30978404, PMID 37163622, PMID 26920463, PMID 29136445, PMID 30794314, PMID 31100455, PMID 31442495, PMID 32502548, PMID 32896653, PMID 33259921, PMID 38407859, PMID 39956162, PMID 40023371, PMID 40204253